Last updated: April 24, 2026
Who supplies BUTRANS active and finished manufacturing?
BUTRANS is a branded buprenorphine transdermal system. Product supply is split across (1) active pharmaceutical ingredient (API) manufacture, (2) dosage form or finished drug product (FDP) production, and (3) device/packaging components tied to the transdermal delivery system. The most consistently documented supply chain in public disclosures is:
- API (buprenorphine) suppliers: Commercial API manufacturers supply buprenorphine used for branded and generic buprenorphine products.
- Drug product (transdermal system) manufacturers: Specialty pharmaceutical manufacturers produce the transdermal system under controlled manufacturing arrangements for Endo/Indivior (brand holder history varies by jurisdiction and period).
- Tapered delivery system and packaging suppliers: Packaging materials and transdermal system components are sourced from regulated packaging and device supply networks used in transdermal manufacturing.
However, public sources that definitively name specific legal entities as “the” suppliers for BUTRANS at the finished dosage level are limited in open literature without pulling program-specific filings that are not provided here. As a result, the only accurate, non-speculative “supplier” statements that can be made from this dataset are structural (API vs. finished drug product vs. packaging) rather than entity-named.
Which supplier categories matter for BUTRANS procurement and contracting?
For procurement and competitive intelligence, the supplier categories map to controllable cost and risk nodes:
| Supplier category |
What they supply |
Typical contract drivers |
| API manufacturer |
Buprenorphine (raw/API) |
DMF readiness, impurity profile capability, batch traceability |
| Drug product manufacturer (FDP) |
Transdermal buprenorphine system (formulation + assembly) |
Adhesive system consistency, membrane control, system release specs |
| Packaging supplier |
Outer cartons, labels, protective pouches/liners, unit seals |
Serialization readiness, tamper evidence, stability constraints |
What does regulatory labeling imply about supply chain governance?
BUTRANS is regulated as a transdermal drug product; as such, the supply chain is governed through:
- NDA/ANDA manufacturing controls for drug product and packaging
- GMP batch documentation and release testing aligned to the labeled specifications
- Traceability from component receipt through finished batch release
These requirements constrain supplier qualification to facilities with established GMP compliance and documentation systems, which is why transdermal drug product supply is concentrated in a smaller set of specialized manufacturers versus commodity API supply.
What procurement terms typically determine which supplier wins for BUTRANS?
For transdermal products like BUTRANS, buyer selection usually turns on:
- Transfer readiness: ability to transfer the manufacturing process and specs without material changes
- Stability performance: impact of adhesives, backing films, and sealing materials
- Device-like consistency: reproducibility of dose delivery across lots
- Regulatory documentation: DMF linkage for API and CMC support for FDP and packaging
How to interpret “suppliers” in competitive intelligence for BUTRANS
In practice, “suppliers for BUTRANS” in an investment or R&D context usually means one of three things:
- API source (who makes buprenorphine)
- FDP producer (who assembles and manufactures the transdermal system)
- Component/packaging network (who supplies primary packaging materials and delivery-system components)
Without entity-specific evidence tied to the exact ANDA/NDA manufacturing site list for the current commercial product, any named supplier would be guesswork.
Key takeaways
- BUTRANS supply is split into API, finished transdermal drug product, and packaging/component supply.
- Procurement and risk concentrate at the FDP and transdermal-system component levels, not only at API sourcing.
- Entity-level supplier naming cannot be completed accurately from the available dataset without program-specific manufacturing site disclosures tied to the current commercial product.
FAQs
1) Are BUTRANS suppliers the same as generic buprenorphine patch suppliers?
Not necessarily. API suppliers can overlap, but finished dosage form (transdermal system) manufacturing and packaging are often performed by different specialized GMP sites.
2) What supplier category has the biggest impact on batch-to-batch consistency for BUTRANS?
The drug product manufacturer and their transdermal system components (membrane, backing, adhesive layer) because they drive dose release performance.
3) Does the API supplier determine the clinical performance of BUTRANS?
Clinical performance is driven by the entire system. API quality matters, but delivery-system engineering and finished product assembly typically dominate release kinetics.
4) What documentation links suppliers to the commercial BUTRANS product?
NDA/DMF and CMC manufacturing site listings for API and FDP, plus packaging documentation for label/packaging components.
5) Why is entity-level supplier identification hard from public sources?
Transdermal products involve contract manufacturing and component procurement, and public materials often describe quality and regulatory control without naming every supplier entity.
References
[1] FDA. “Drug Supply Chain Security Act (DSCSA) and pharmaceutical supply chain regulatory framework.” U.S. Food and Drug Administration.
[2] FDA. “Current Good Manufacturing Practice (CGMP) for finished pharmaceuticals.” U.S. Food and Drug Administration.
[3] FDA. “Abbreviated New Drug Application (ANDA) and CMC manufacturing information requirements.” U.S. Food and Drug Administration.
